FLSM
ENGN icon

Frazier Life Sciences Management’s enGene Therapeutics ENGN Stock Holding History

Frazier Life Sciences Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,157,380
Closed -$7.9M – 45
2025
Q3 		$7.9M Buy
+1,157,380
New +$5.28M 0.24% 42

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Life Sciences Management's ENGN Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of enGene Therapeutics (ENGN) in Q4 2025, closing a stake of 1,157,380 shares — an estimated $7.9M sold.

Frazier Life Sciences Management first reported a position in ENGN in Q3 2025 and held it in 1 quarter. The position peaked at $7.9M in Q3 2025. 57 funds tracked by Wall St. Rank hold ENGN as of Q4 2025.

  • Frazier Life Sciences Management reported no remaining enGene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,157,380 enGene Therapeutics shares in Q4 2025, an estimated $7.9M.
  • Frazier Life Sciences Management first reported a position in enGene Therapeutics in Q3 2025 and held it in 1 quarter.
  • Frazier Life Sciences Management's enGene Therapeutics position peaked at $7.9M in Q3 2025.
  • 57 funds tracked by Wall St. Rank held enGene Therapeutics as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.